Ruby Prosser Scully

Australia

Managing Editor at The Medical Republic

Managing editor @medicalrepublic. Bylines in @newscientist, @guardian, @Nature, @cosmosmagazine and others. @[email protected]

Featured in: Favicon

medicalrepublic.com.au Favicon

theguardian.com Favicon

nature.com Favicon

newscientist.com Favicon

realclearscience.com Favicon

dermatologyrepublic.com.au Favicon

oncologyrepublic.com.au

Articles

‘Milestone’ GDM guidelines raise thresholds

6 days ago | medicalrepublic.com.au | Ruby Prosser Scully

Concerns about overdiagnosis appear to have been heard, with the update expected to reduce the amount of low-risk women labelled with the condition. Fewer low risk pregnant women are expected to be diagnosed with gestational diabetes, thanks to the first new national guidelines in a decade. The Australasian Diabetes in Pregnancy Society (ADIPS) guidelines raise the glucose threshold needed for a diagnosis in early and late pregnancy.
Psychodermatology: treat the itch first

1 week ago | medicalrepublic.com.au | Ruby Prosser Scully

Doctors may find patients difficult, but there are some straightforward steps to managing delusions of parasitosis. Patients with suspected delusional parasitosis should be treated dermatologically rather than being immediately referred to a psychiatrist or psychologist, says one expert.
Exciting updates in rosacea management

2 weeks ago | medicalrepublic.com.au | Ruby Prosser Scully

A new treatment algorithm and drug developments prompt hope for one in 10 Australians who have this condition. An updated treatment algorithm for the treatment of rosacea, alongside promising drug developments, offer hope to Australian rosacea patients.
Terrorism ‘imprints’ on the body

1 month ago | medicalrepublic.com.au | Ruby Prosser Scully

Survivors may have lasting changes to their stress, immunological and cardiovascular functioning. Terrorism may have lasting effects on biological stress, according to research on survivors of the 1995 Oklahoma City bombing. The research found that even if the participants had otherwise healthy lives, there were physiological traces of the event up to seven years later.
GLP1-RAs don't worsen mental health

1 month ago | medicalrepublic.com.au | Laura Andronicos |Ruby Prosser Scully

And antidepressant withdrawal may be harder after longer use, while depression and loneliness predicts future pain. GLP1-RA drugs don’t seem to trigger adverse psychiatric events and instead appear to improve both physical and emotional wellbeing, a UK systematic review and meta-analysis found.
Bedtime BP meds get green light

1 month ago | medicalrepublic.com.au | Ruby Prosser Scully

Patient preference may be the most important thing when it comes to timing their intake, promising safety and efficacy data suggests. Patients who take their blood pressure medication at night have no greater health risks than those who take it in the morning, according to new Canadian research. The findings suggest patient preference can play more of a role in when the medicines are taken, overturning the conventional morning approach.
New promise for advanced non-small cell lung cancer

1 month ago | oncologyrepublic.com.au | Ruby Prosser Scully

Ivonescimab monotherapy hinted at better progression-free survival than its rival and has been approved by China’s regulator. Ivonescimab monotherapy improves progression-free survival in patients with PD-L1–expressing advanced non-small cell lung cancer (aNSCLC) compared with pembrolizumab, new Chinese research suggests.
Nivolumab with ipilimumab gets FDA tick

1 month ago | oncologyrepublic.com.au | Ruby Prosser Scully

Adults with unresectable or metastatic liver cancer now have access to the combination for first-line therapy. US adults now have access to nivolumab with ipilimumab for the first-line treatment of unresectable hepatocellular carcinoma, thanks to new FDA approval. The regulator announced the move on 11 April, citing efficacy and safety data from the CHECKMATE-9DW trial of almost 700 adults with unresectable or metastatic HCC.
TGA alert for RSV vaccines

1 month ago | puffnstuff.com.au | Ruby Prosser Scully

The product information of Arexvy and Abrysvo has been updated to include the rare risk of Guillain-Barre syndrome. Login Join Now This content is for members only.
TGA alert for RSV vaccines

1 month ago | medicalrepublic.com.au | Ruby Prosser Scully

The product information of Arexvy and Abrysvo has been updated to include the rare risk of Guillain-Barre syndrome. Login Join Now This content is for members only.